Suppr超能文献

感染猕猴 SIVmac251 后,自体中和抗体针对传播/原始病毒的出现较晚。

Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.

机构信息

Division of Viral Pathogenesis, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.

出版信息

J Virol. 2010 Jun;84(12):6018-32. doi: 10.1128/JVI.02741-09. Epub 2010 Mar 31.

Abstract

While the simian immunodeficiency virus (SIV)-infected rhesus monkey is an important animal model for human immunodeficiency virus type 1 (HIV-1) infection of humans, much remains to be learned about the evolution of the humoral immune response in this model. In HIV-1 infection, autologous neutralizing antibodies emerge 2 to 3 months after infection. However, the ontogeny of the SIV-specific neutralizing antibody response in mucosally infected animals has not been defined. We characterized the kinetics of the autologous neutralizing antibody response to the transmitted/founder SIVmac251 using a pseudovirion-based TZM-bl cell assay and monitored env sequence evolution using single-genome amplification in four rhesus animals that were infected via intrarectal inoculations. We show that the SIVmac251 founder viruses induced neutralizing antibodies at 5 to 8 months after infection. Despite their slow emergence and low titers, these neutralizing antibodies selected for escape mutants that harbored substitutions and deletions in variable region 1 (V1), V2, and V4 of Env. The neutralizing antibody response was initially focused on V4 at 5 to 8 months after infection and then targeted V1/V2 and V4 by 16 months. These findings reveal a striking delay in the development of neutralizing antibodies in SIVmac-infected animals, thus raising questions concerning the suitability of SIVmac251 as a challenge strain to screen AIDS vaccines that elicit neutralizing antibodies as a means to prevent virus acquisition. They also illustrate the capacity of the SIVmac quasispecies to modify antigenic determinants in response to very modest titers of neutralizing antibodies.

摘要

虽然感染猴免疫缺陷病毒(SIV)的恒河猴是研究人类免疫缺陷病毒 1 型(HIV-1)感染人类的重要动物模型,但我们对该模型中体液免疫反应的进化仍知之甚少。在 HIV-1 感染中,自体中和抗体在感染后 2 至 3 个月出现。然而,黏膜感染动物中 SIV 特异性中和抗体反应的发生机制尚未确定。我们使用基于假病毒的 TZM-bl 细胞测定法,对通过直肠内接种感染的四只恒河猴中的 SIVmac251 进行了鉴定,并用单基因组扩增法监测了 env 序列的进化,以研究 SIVmac251 自体中和抗体的动力学。我们发现,SIVmac251 原始病毒在感染后 5 至 8 个月诱导中和抗体。尽管这些中和抗体出现缓慢且效价低,但它们选择了逃逸突变体,这些突变体在 Env 的可变区 1(V1)、V2 和 V4 中具有取代和缺失。中和抗体反应最初集中在感染后 5 至 8 个月的 V4 上,然后在 16 个月时针对 V1/V2 和 V4。这些发现揭示了 SIVmac 感染动物中中和抗体发展的明显延迟,这引发了对 SIVmac251 作为挑战株的适用性的质疑,该病毒可引发中和抗体作为预防病毒获得的手段。它们还说明了 SIVmac 准种根据中和抗体的非常低的效价来改变抗原决定簇的能力。

相似文献

4
Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.
Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10780-5. doi: 10.1073/pnas.1509731112. Epub 2015 Aug 10.

引用本文的文献

2
Antiretroviral therapy reveals triphasic decay of intact SIV genomes and persistence of ancestral variants.
Cell Host Microbe. 2023 Mar 8;31(3):356-372.e5. doi: 10.1016/j.chom.2023.01.016. Epub 2023 Feb 20.
4
SIV infection duration largely determines broadening of neutralizing antibody response in macaques.
J Clin Invest. 2020 Oct 1;130(10):5413-5424. doi: 10.1172/JCI139123.
5
The -HIV syndemic interaction: why treating infection may be crucial for HIV-1 eradication.
Future Virol. 2020 Feb;15(2):101-125. doi: 10.2217/fvl-2019-0069.
7
Persistence of SIV in the brain of SIV-infected Chinese rhesus macaques with or without antiretroviral therapy.
J Neurovirol. 2018 Feb;24(1):62-74. doi: 10.1007/s13365-017-0594-0. Epub 2017 Nov 27.
8
The HIV-1 transmission bottleneck.
Retrovirology. 2017 Mar 23;14(1):22. doi: 10.1186/s12977-017-0343-8.
9
Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.
PLoS Pathog. 2016 Apr 11;12(4):e1005537. doi: 10.1371/journal.ppat.1005537. eCollection 2016 Apr.
10
Recombination Enhances HIV-1 Envelope Diversity by Facilitating the Survival of Latent Genomic Fragments in the Plasma Virus Population.
PLoS Comput Biol. 2015 Dec 22;11(12):e1004625. doi: 10.1371/journal.pcbi.1004625. eCollection 2015 Dec.

本文引用的文献

1
Virology. Moving forward in HIV vaccine development.
Science. 2009 Nov 27;326(5957):1196-8. doi: 10.1126/science.1183278.
3
Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.
PLoS Pathog. 2009 Sep;5(9):e1000598. doi: 10.1371/journal.ppat.1000598. Epub 2009 Sep 18.
4
Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.
PLoS Pathog. 2009 Sep;5(9):e1000594. doi: 10.1371/journal.ppat.1000594. Epub 2009 Sep 18.
5
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection.
J Exp Med. 2009 Jun 8;206(6):1253-72. doi: 10.1084/jem.20090365. Epub 2009 Jun 1.
6
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1.
J Exp Med. 2009 May 11;206(5):1117-34. doi: 10.1084/jem.20082831. Epub 2009 May 4.
7
Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India.
Virology. 2009 Mar 15;385(2):505-20. doi: 10.1016/j.virol.2008.12.032. Epub 2009 Jan 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验